PO-SCORAD for black skin is a simple tool that allows patients to easily self-assess atopic dermatitis severity. It may prove a valuable tool for monitoring disease severity between physician visits and involving patients in the management of their disease.
Although the atopic dermatitis treatment patterns found reflect existing clinical guidelines, second-generation antihistamines are not recommended in the management of atopic dermatitis, despite being the third most prescribed medication class.
Data from this analysis indicate that dupilumab induces rapid improvements in AD that can be maintained long term in a significant percentage of Japanese adults with moderate to severe AD, with prolonged benefits in terms of both pruritus and QoL.
The study data showed a 20% increased long-term risk for atrial fibrillation in patients with hospital-diagnosed moderate to severe atopic dermatitis.
Pfizer announced positive topline results from the phase 3 JADE MONO-2 trial of abrocitinib, an oral Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis.
This study supports the use of dupilumab as a systemic treatment for long-term management of moderate to severe AD without routine laboratory monitoring in clinical practice.
From the patient’s perspective, higher atopic dermatitis severity is associated with poorer HRQoL — a burden that may provide motivation for more effective management of atopic dermatitis.
Notable improvement with dupilumab in the treatment of moderate to severe atopic dermatitis was seen in all racial subgroups.
Study findings suggest that temperature, relative humidity, and air pollution are significantly associated with outpatient visits for atopic dermatitis.
Treatment varies greatly for pediatric patients with atopic dermatitis as drugs with known risks continue to be popular and beneficial agents are rarely prescribed.